Should we use poor prognosis factors to start early treatment in patients with rheumatoid arthritis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Reumatología Clínica

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.REUMAE.2012.06.010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyanoacrylate microbial sealants for skin preparation prior to surgery.

  2013cited by this paper
• Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor.

  2011cited by this paper
• Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

  2011cited by this paper
• In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

  2011cited by this paper
• UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

  2011cited by this paper
• Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression

  2011cited by this paper
• Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

  2011cited by this paper
• Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.

  2011cited by this paper
• Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes

  2011cited by this paper
• The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study

  2011cited by this paper
• Anti-CCP antibodies: the past, the present and the future

  2011cited by this paper
• Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment

  2011cited by this paper
• Treating rheumatoid arthritis to target: recommendations of an international task force

  2010cited by this paper
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

  2010cited by this paper
• Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative

  2010cited by this paper
• RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis

  2010cited by this paper
• Importance of research on peptidylarginine deiminase and citrullinated proteins in age‐related disease

  2010cited by this paper
• Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.

  2010cited by this paper
• A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study

  2010cited by this paper
• Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals.

  2010cited by this paper
• Mixed response to tocilizumab for ankylosing spondylitis

  2010cited by this paper
• The assessment of disease activity in rheumatoid arthritis.

  2010cited by this paper
• Peptidylarginine deiminase 4 and citrullination in health and disease.

  2010cited by this paper
• Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER

  2010cited by this paper
• Predictors for remission in rheumatoid arthritis patients: A systematic review

  2010cited by this paper
• Relationship Between Rheumatoid Factor Isotypes and IgG Anti-Cyclic Citrullinated Peptide Antibodies

  2010cited by this paper
• A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.

  2009cited by this paper
• Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.

  2009cited by this paper
• Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.

  2009cited by this paper
• Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis.

  2009cited by this paper
• Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab bef

  2009cited by this paper
• A case-control study on occupational risk factors for sino-nasal cancer

  2009cited by this paper
• Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population.

  2009cited by this paper
• Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis

  2009cited by this paper
• Periodontitis in systemic rheumatic diseases

  2009cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

  2008cited by this paper
• Spondylarthritis in the absence of B lymphocytes.

  2008cited by this paper
• Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.

  2008cited by this paper
• Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.

  2008cited by this paper
• Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis

  2008cited by this paper
• Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.

  2008cited by this paper
• Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles.

  2007cited by this paper
• Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients

  2007cited by this paper
• Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial

  2007cited by this paper
• Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

  2007cited by this paper
• Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

  2007cited by this paper
• Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis.

  2006cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Citrullination: a posttranslational modification in health and disease.

  2006cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis.

  2006cited by this paper
• Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.

  2006cited by this paper
• Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

  2005cited by this paper
• Human B Cell Tolerance and Its Failure in Rheumatoid Arthritis

  2005cited by this paper
• Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis

  2005cited by this paper
• The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

  2005cited by this paper
• The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.

  2005cited by this paper
• The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

  2005cited by this paper
• Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

  2005cited by this paper
• Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis

  2005cited by this paper
• Impaired early B cell tolerance in patients with rheumatoid arthritis

  2005cited by this paper
• The presence of citrullinated proteins is not specific for rheumatoid synovial tissue.

  2004cited by this paper
• Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)

  2004cited by this paper
• Histone deimination antagonizes arginine methylation.

  2004cited by this paper
• A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis

  2004cited by this paper
• Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin

  2004cited by this paper
• Human PAD4 Regulates Histone Arginine Methylation Levels via Demethylimination

  2004cited by this paper
• Clinical utility of the anti-CCP assay in patients with rheumatic diseases

  2003cited by this paper
• A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

  2003cited by this paper
• The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing.

  2003cited by this paper
• Predominant Autoantibody Production by Early Human B Cell Precursors

  2003cited by this paper
• Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

  2003cited by this paper
• Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

  2003cited by this paper
• ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets.

  2003cited by this paper
• Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis.

  2002cited by this paper
• The Major Synovial Targets of the Rheumatoid Arthritis-Specific Antifilaggrin Autoantibodies Are Deiminated Forms of the α- and β-Chains of Fibrin1

  2001cited by this paper
• Links between radiological change, disability, and pathology in rheumatoid arthritis.

  2001cited by this paper
• Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis.

  2001cited by this paper
• Studies on specificity of peptidylarginine deiminase reactions using an immunochemical probe that recognizes an enzymatically deiminated partial sequence of mouse keratin K1.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages.

  1998cited by this paper
• Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

  1998cited by this paper
• Deimination of 70-kD Nuclear Protein During Epidermal Apoptotic Events In Vitro

  1998cited by this paper
• Acute multiple sclerosis (marburg type) is associated with developmentally immature myelin basic protein

  1996cited by this paper
• The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.

  1995cited by this paper
• Myelin in multiple sclerosis is developmentally immature.

  1994cited by this paper
• Antikeratin antibodies in rheumatoid arthritis

  1991cited by this paper
• Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

  1991cited by this paper
• [Antikeratin antibodies in rheumatoid arthritis].

  1991cited by this paper
• Anti-keratin antibodies in rheumatoid arthritis.

  1979cited by this paper
• New Serum Factor in Patients with Rheumatoid Arthritis: The Antiperinuclear Factor *

  1964cited by this paper
• Extended Report

  year unknowncited by this paper

• The Relationship Between Porphyromonas Gingivalis and Rheumatoid Arthritis: A Meta-Analysis

  2022cites this paper